Non-Invasive Evaluation of Hepatic Fibrosis for Type C Chronic Hepatitis
Chie Tatsumi(Kindai University), Tsuyoshi Shiina(Shibaura Institute of Technology), Masatoshi Kudo(Kindai University), Satoshi Kitai(Kindai University), Yasunori Minami(Kindai University), Hobyung Chung(Kindai University), Kazuomi Ueshima(Kindai University), Michio Kato, Tatsuo Inoue, Kenji Fujimoto(National Hospital Organization), Emi Ishikawa(Kyowa Chemical Industry (Japan)), Norihisa Yada(Kindai University), Akiko Tonomura(Hitachi (Japan)), Tsuyoshi Mitake(Hitachi (Japan)), Kiyoshi Maekawa(Kindai University), Satoru Hagiwara(Kindai University Hospital)
Cited by 79
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k